Cardiovascular safety of biologic therapies in patients with severe asthma: a nationwide cohort study in Belgium.

ABSTRACT:

Background

In last decades, biologic therapies have been approved for severe allergic and/or eosinophilic asthma. Limited studies have investigated the effect of biologics on (acute) cardiovascular events, which have reported conflicting results. We aimed to investigate the potential cardiovascular risk of anti-immunoglobulin(Ig)-E (omalizumab) and anti-interleukin(IL)-5/IL5 receptor (IL5R) therapies (mepolizumab and benralizumab) in patients with severe asthma compared with non-biologic users.

Methods

Adult asthma patients eligible for biologics were identified in Belgian nationwide data between 2017 and 2022. Inverse probability of treatment weighted Cox regression was used to investigate cardiovascular outcomes and all-cause mortality, while controlling for age, sex, obes

SUBMITTER: Van Vaerenbergh F 

PROVIDER: S-EPMC12355080 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature